Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

BACKGROUND: Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Carreau, Nicole A., Pail, Orrin, Armand, Philippe, Merryman, Reid, Advani, Ranjana H., Spinner, Michael A., Herrera, Alex, Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad S., Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven, Barta, Stefan, Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin, Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali, Godfrey, James, Chavez, Julio, Xia, Yuhe, Troxel, Andrea B., Diefenbach, Catherine
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Hematologic Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543382/
https://ncbi.nlm.nih.gov/pubmed/32720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados